The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.

As described before, the fraction of Ter119 + erythroid cells was decreased in the BM of BCR-ABL positive mice and reversed by dasatinib (even though this did not reach statistical significance), while there was no significant BCR-ABL induced change of Ter119 + cells in the spleen; yet, the fraction of these cells was increased in the spleen of BCR-ABL positive but not control mice (Figure 2B ).

also in 111,027 other papers